🔎 Trials Near Me

Home › Knee Osteoarthritis › NCT07641517

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain

RecruitingPhase 2

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Osteoarthritis

Who can join

Ages 40 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Have presence of index knee pain for more than 12 weeks at screening
* Have an x-ray supporting diagnosis of osteoarthritis according to the American College of Rheumatology with a Kellgren-Lawrence grade 2 to 4 radiographic classification of index knee
* Have a body mass index ≤40 kilograms per meter squared (kg/m²) (inclusive)
* Have stable glycemic control as indicated by a glycated hemoglobin (HbA1c) less than or equal to 10 at time of screening

Exclusion Criteria:

* Are pregnant or breastfeeding
* Have had a surgical procedure or therapeutic injection in the affected knee within 3 months prior to screening
* Have presence of surgical hardware or other foreign body in the index knee
* Have ongoing complex regional pain syndrome or other concurrent medical condition that could interfere with the evaluation of pain in the index knee.
* Have had any joint replacement of the lower extremity, such as hip, knee or ankle, in the 6 months prior to screening
* Have an abnormal blood pressure (BP) (systolic BP greater than 140 millimeters mercury (\>140 mm Hg) and diastolic BP\>90 mm Hg) at screening
* Have history or current clinically significant cardiac disease, including arrhythmia, aortic aneurysm, heart failure, current electrolyte abnormalities, or any other conditions that could predispose to arrhythmia in the judgement of the investigator

About the study

The main purpose of this study is to test the safety and efficacy of study drug for the treatment of knee pain due to osteoarthritis (OA). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.

What is being tested

Sponsor: Eli Lilly and Company · Participants: 150 · Started: Jun 25, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07641517

Locations in the U.S.

AlabamaCentral Research Associates, Birmingham
ArizonaArizona Research Center, Phoenix
Synexus Clinical Research US, Inc., Phoenix
CaliforniaDesert Oasis Healthcare Medical Group, Palm Springs
Artemis Institute for Clinical Research, Riverside
Artemis Institute for Clinical Research, San Diego
ConnecticutCMR of Greater New Haven, Hamden
FloridaBradenton Research Center, Inc., Bradenton
Accel Research Sites - DeLand Clinical Research Unit, DeLand
K2 MEDICAL Research THE VILLAGES, Lady Lake
K2 Medical Research ORLANDO, Maitland
Merritt Island Medical Research, LLC, Merritt Island
New Horizon Research Center, Miami
Suncoast Research Group, Miami
Suncoast Clinical Research, Inc., New Port Richey
Renstar Medical Research, Ocala
Precision Clinical Research, Sunrise
Charter Research - Lady Lake, The Villages
Conquest Research, Winter Park
GeorgiaNorth Georgia Clinical Research, Woodstock
IllinoisNorthwestern University, Chicago
LouisianaDelRicht Research, New Orleans
MassachusettsLucida Clinical Trials, New Bedford
MedVadis Research Corporation, Waltham
MichiganGreat Lakes Research Group, Inc., Bay City
MissouriStudyMetrix Research, City of Saint Peters
Clinvest Research LLC, Springfield
New YorkRochester Clinical Research, LLC, Rochester
North DakotaLillestol Research, Fargo
OhioMETA Medical Research Institute, Dayton
OklahomaDelRicht Research, Tulsa
PennsylvaniaAltoona Center For Clinical Research, Duncansville
TexasFutureSearch Trials of Neurology, Austin
Re:Cognition Health - Fort Worth, Fort Worth
WashingtonNorthwest Clinical Research Center, Bellevue
Rainier Clinical Research Center, Renton

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.